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A range of antimicrobial peptides (AMP) exhibit activity on malaria parasites, Plasmodium
spp., in their blood or mosquito stages, or both. These peptides include a diverse array
of both natural and synthetic molecules varying greatly in size, charge, hydrophobicity,
and secondary structure features. Along with an overview of relevant literature reports
regarding AMP that display antiplasmodial activity, this review makes a few considerations
about those molecules as a potential new class of antimalarial drugs.
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INTRODUCTION
NATURAL ANTIMICROBIAL PEPTIDES: SOLDIERS IN THE BODY’S FIRST
LINE OF DEFENSE
Once the organism is invaded by a pathogen, a primary response
from the host immune system comprises production of speciﬁc
peptides as defense compounds. Several of these humoral response
peptides exert antibacterial, antifungal, or antiviral properties
(Bulet et al., 1999) and are known as host defense peptides, or
antimicrobial peptides (AMP; Bell, 2011). Hence, AMP form
the ﬁrst line of host defense against infection and are a key
component of the ancient innate immune system. Most AMP
are small amphipathic peptides, usually with 15–45 amino acid
(AA) residues, and, in general, are cationic at physiological pH
(Boman, 2003).
Antimicrobial peptides, which may be encoded by sepa-
rate genes or produced by non-ribosomal biosynthesis, have
been identiﬁed in various species from bacteria to insects,
amphibians to mammals, including humans (Zasloff, 2002; Pele-
grini et al., 2011). In insects, AMP are synthesized in the fat
body, in hemocytes, or epithelia, and are released into the
hemolymph. In vertebrates, AMP are present in amphibian
skin secretions (Simmaco et al., 1999) and epithelia (Ganz and
Weiss, 1997; Bals et al., 1998); in mammals, AMP are also
observed in lymphocytes (Agerberth et al., 2000) and leukocytes
(Sorensen et al., 1997).
Because of their broad activity against microbes, and their
expression triggered by various infections, AMP have been
intensely examined as potential therapeutic agents (Zasloff,
2002). In 2004, the antimicrobial peptide database (APD,
http://aps.unmc.edu/AP/main.php), created at the University of
Nebraska Medical Center, already gathered a signiﬁcant number
of AMP that had been discovered at both the gene and protein
levels (Wang and Wang, 2004). Later, APD has been updated and
expanded to a second version that allows users to search peptides
by families (e.g., bacteriocins, cyclotides, or defensins), sources
(e.g., ﬁsh, frogs, or chicken), post-translationalmodiﬁcations (e.g.,
amidation, oxidation, lipidation, glycosylation, or inclusion of D-
AA), and binding targets [e.g., cell membranes, proteins, nucleic
acids, lipopolysaccharides (LPSs), or other sugars; Wang et al.,
2009]. Today, there is a huge plethora of AMP of both natural and
synthetic origin, as recently reviewed elsewhere (Som et al., 2008;
Rotem and Mor, 2009; Kuroda and Gaputo, 2013; Pushpanathan
et al., 2013; Sgolastra et al., 2013), highlighting AMP as relevant
antibiotics (Fjell et al., 2011).
ORGANIZING DIVERSITY: STRUCTURE-BASED CLASSIFICATION OF
ANTIMICROBIAL PEPTIDES
The diversity of AMP reported since earlier disclosures in this
area has soon made clear that some organization/classiﬁcation
of AMP families was needed. For instance, Boman (2003)
proposed AMP to be split into three major groups: (a) lin-
ear α-helical peptides free of cysteine residues; (b) β-pleated
peptides containing disulﬁde bridges; (c) peptides with an over-
representation of certain AA, such as proline, arginine, tryp-
tophan, or histidine. However, peptides that did not ﬁt into
any of these groups were later found to be antimicrobial, as
is the case of circular peptides like θ-defensins (Lehrer et al.,
2012) or cyclotides (Jagadish and Camarero, 2010). Hence,
at present, four main types of AMP can be roughly distin-
guished:
α-helical peptides deprived of Cys residues
Linear cationic α-helical AMP are a class of small peptides
whose charge is imparted by the presence of multiple Lys
and Arg, but also with a substantial portion (50% or more)
of hydrophobic residues. These peptides are known for their
broad-spectrum antimicrobial activity and ability to modu-
late the innate immune response (Powers and Hancock, 2003).
One example is that of melittin, an α-helical cationic pep-
tide from the venom of Apis mellifera bees, composed of 26
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AA residues and in which the amino-terminal region is pre-
dominantly hydrophobic whereas the carboxy-terminal region
is hydrophilic due to the presence of a stretch of positively
charged AA (Raghuraman and Chattopadhyay, 2007). Melittin
is a potent antimicrobial that seems to promote membrane per-
meabilization through pore formation according to the toroidal
model (Yang et al., 2001). However, its hemolytic activity is too
high for clinical application as a selective AMP, which led to
studies addressing synthesis and evaluation of the antimicrobial
potential of hybrid peptide constructs where melittin (entire or
partial AA sequence) was combined with other non-hemolytic
AMP, such as cecropins (Boman et al., 1989; Bastos et al., 2008;
López-Rojas et al., 2011). Cecropins constitute a well-known
family of α-helical AMP that share a similar structure contain-
ing two α-helical domains linked by a ﬂexible region. Insect
cecropins are known to induce pore formation in negatively-
charged bacterial membranes (Ekengren and Hultmark, 1999;
Tanaka et al., 2008). In turn, a positive surface charge or choles-
terol present in the membrane bilayer decreases the channel
formation potency of cecropins (Christensen et al., 1988), which
explains why these have little or no effect on eukaryotic cells
(being non-hemolytic) that are richer in zwitterionic phospho-
lipids and contain a high amount of cholesterol as compared
to bacteria (Yeaman and Yount, 2003; Beevers and Dixon, 2010;
Pretzel et al., 2013).
Other widely studied families of α-helical, linear and cysteine-
free AMP are those of magainins and dermaseptins, both naturally
occurring in amphibians. Magainins 1 and 2 adopt an α-helical
conformation in solution (Zasloff, 1987), and have been pro-
posed to induce toroidal pores in bacterial membranes (Ludtke
et al., 1996). The non-hemolytic character of magainin 2 and
its protocidal activity underlie its interest as a potential anti-
parasitic agent, and also as a template for creation of more
potent large spectrum AMP analogs, such as pexiganan (Ge
et al., 1999). In what concerns peptides from the dermaseptin
super-family, these exhibit a broad range of antimicrobial activity
and some of them were found to aggregate on the bacte-
rial membrane surface in a carpet-like manner (Pouny et al.,
1992).
β-pleated peptides containing disulﬁde bridges
A classical example of this group of AMP is that of defensins,
peptides mostly found in mammalian phagocytes that usually
contain six Cys residues (eight Cys have been found in some
insect defensins) stabilizing peptide structure by forming three
intramolecular disulﬁde bridges (Selsted et al., 1985). The mech-
anism of action of these peptides seems to also involve pore
formation inducing membrane permeabilization, which is more
extensive on negatively charged phospholipid bilayers (Lehrer
et al., 1989; Wimley et al., 1994).
Peptides rich in Pro, Gly, His, Arg, and Trp residues
This is a somewhat more heterogeneous group of AMP, as those
included are diverse in sequence and tridimensional structure,
sharing the feature of having an overrepresentation of certain
AA, speciﬁcally, Pro, Gly, His, Arg, and Trp. From this follows
that AMP of this group seem to also have diverse mechanisms
of antimicrobial action, in some cases apparently involving
intracellular targets (Otvos, 2005).
A family of Pro-rich AMP is that of apidaecins, short peptides
that may adopt a polyproline type II helical structure which could
be the structural basis to bind to speciﬁc targets underlying its
antibacterial activity (Li et al., 2006). In fact, apidaecins do not
seem to interact with microbial membranes through formation
of pores, but rather by an energy-driven, eventually transporter-
mediated, process (Castle et al., 1999).
Gly-rich AMP have been found with variable sizes and with-
out any clear sequence signature, apart from the high proportion
(25–50%) of glycine residues. These peptides are in general
longer than AMP from other classes, have disordered structure
in water, and tend to self-order when in contact with artiﬁcial
membranes (Bruston et al., 2007). Attacins are family of six Gly-
rich AMP that can be divided into four basic (A–D) and two
acidic (E–F) peptides, probably derived from two attacin genes
(Yi et al., 2014). Attacins inhibit the synthesis of outer mem-
brane proteins of Escherichia coli by blocking transcription of
the respective genes (Carlsson et al., 1991), which is presumably
achieved by an indirect mechanism, since attacins bind to the bac-
terial LPS but do not need to enter the cell to exert their action
(Carlsson et al., 1998).
Tryptophan-rich AMP contain more than 25% of this amino
acid. In what concerns this class of AMP, the archetypical example
is that of indolicin,which adopts no particular secondary structure
inwater, but seems to undergo signiﬁcant structural changes in the
vicinity of lipid bilayers, explaining its strong membrane afﬁnity
underlying its antimicrobial activity (Ladokhin and White, 2001).
This peptide has the ability to permeate bacterial membranes and,
depending of its tridimensional shape, inhibits DNA synthesis by
binding to it (Hsu et al., 2005). Other examples of Trp-rich AMP
include tritrpticin (Lawyer et al., 1996), lactoferricin B (Bellamy
et al., 1992), and Pac-525 (Wei et al., 2006).
His-rich AMP usually have 25% of their AA content rep-
resented by His. In general, these peptides show a cationic
amphipathic helical structure, and trigger microbial membrane
disruption when adopting an alignment parallel to the mem-
brane surface. Still, pore formation is not essential for the high
antimicrobial activity of many His-rich AMP (Mason et al., 2009).
Clavanin (van Kan et al., 2002), daptomycin (Jeu and Fung, 2004),
LAH4 (Bechinger, 1996), or D-HALO-rev (Mason et al., 2009) are
a few examples of this class of AMP.
Circular antimicrobial peptides
Discovery of antimicrobial activity on natural cyclic peptides that
did not ﬁt any of the previous three groups justiﬁes the need to
consider a fourth group, dedicated to circular AMP. θ-defensins,
for instance, ﬁt this group: they are cyclic octadecamers active
against several Gram-positive and Gram-negative bacteria, fungi,
and some viruses, which consist of a couple of antiparallel β-sheets
linked by three disulﬁde bonds to produce a very stable structure
(Lehrer et al., 2012). Some bacteriocins, which are polypeptide
toxins produced by bacteria to inhibit the growth of competing
bacterial species or strain(s) (Cotter et al., 2013), are also circu-
lar AMP; that is the case of AS-48, a cyclic 70-mer bacteriocin
from Enterococcus faecalis, possessing an overall globular structure
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where ﬁve α-helices enclose a dense hydrophobic core (González
et al., 2000). Finally, one of the most emblematic families of circu-
lar AMP is that of cyclotides (Jagadish and Camarero, 2010): these
are plant-derived peptides, with approximately 30 AA, character-
ized by a head-to-tail cyclic backbone and three or four disulﬁde
bonds forming the so-called cyclic cysteine knot (CCK;Craik et al.,
1999), for which they are also known as “knotted peptides.” As
a result of their singular structure, these peptides are extremely
stable, retaining their biological activity after boiling and being
extremely resistant to enzymatic degradation (Vila-Perelló and
Andreu, 2005; Craik and Conibear, 2011).
ANTIMICROBIAL PEPTIDES: A NEW SOLUTION AGAINST
MALARIA?
A MILLENARY WORLDWIDE DISEASE STILL FAR FROM ERADICATION
Human malaria is caused by any of ﬁve species of protozoal, api-
complexan parasites of the genus Plasmodium, P. vivax, P. ovale,
P. malariae, P. knowlesi, and P. falciparum, the latter being the
most virulent, the best characterized, and (along with P. vivax)
the most widespread species. Rodent malaria parasites such
as P. berghei and P. yoelii, the avian parasite P. gallinaceum,
or the human parasite P. falciparum are the most well-studied
and used to evaluate drug-parasite interactions (Prudêncio et al.,
2006; Dixon et al., 2008; Mantel et al., 2013; Regev-Rudzki
et al., 2013). Parasites of the Apicomplexa are important ani-
mal pathogens notable for their complex life cycles and highly
specialized invasive forms. Besides Plasmodia, apicomplexan
parasites include the agents of toxoplasmosis, cryptosporidio-
sis, and several other signiﬁcant parasitic diseases (WHO, 2012;
Singh and Daneshvar, 2013).
The deﬁnitive host of Plasmodia, the female Anopheles
mosquito, transmits the infective forms of the parasite, sporo-
zoites, to the intermediate host (usually, a mammal) during its
blood meal. After migration to the liver, the parasites develop
within hepatocytes, of which they later exit as merozoites that are
released into the bloodstream. Inside red blood cells (RBC) the
asexual lifecycle takes place, starting by merozoite development
into the ring stage, this in turn evolves to produce metabolically
highly active trophozoites, which ﬁnally give place to schizonts,
responsible for the release of new merozoites to infect other
healthy RBC.Occasionally, ring forms can also develop into female
and male gametocytes that, once ingested by another Anopheles
mosquito, start the sexual lifecycle by developing into ookinetes,
oocysts, and ﬁnally sporozoites, which migrate into the salivary
gland to be transferred to another host on the following blood
meal (Figure 1).
The complex life-cycle of malaria parasites, and the ease at
which these undergo mutations to escape drug pressure, are
the major factors behind both the limitations of current con-
trol methods and the urgent need for new chemoprophylactic
and chemotherapeutic agents. These aspects have been com-
prehensively discussed elsewhere (Philips, 2001; Teixeira et al.,
2014), turning clear that, while antimalarial drugs in use
(mostly artemisinin and derivatives, quinolines or related com-
pounds, and inhibitors of the folate pathway) can be effective
in many situations, improvements in terms of (especially) cost
and safety are highly desirable (Flannery et al., 2013; Visser
et al., 2014; White et al., 2014). Yet, this is a difﬁcult endeavor,
as the mechanisms of action of many antimalarial drugs are
still poorly understood. For instance, the current ﬁrst-line anti-
malarial drugs, artemisinin and related compounds, have been
suggested to eliminate the Ca2+-dependent ATPase activity of
PfATP6 (Eckstein-Ludwig et al., 2003); however, other modes
of action have been attributed to this family of antimalarials
as, e.g., binding to ferriprotoporphyrin IX (a by-product of
hemoglobin degradation), free radical-mediated damage or inter-
ference with hematin polymerization and detoxiﬁcation (Robert
et al., 2002; Biagini et al., 2003). Other antimalarial drugs seem
to target the redox systems of Plasmodia, whose survival is
highly dependent on the antioxidative stress system of their hosts
(Becker et al., 2004). An example is that of chloroquine, for-
merly used as ﬁrst-line treatment for uncomplicated malaria,
which inhibits polymerization of toxic heme (Fe2+) into hemo-
zoin inside the parasite’s food vacuole (Sullivan et al., 1996).
Primaquine, which remains the only transmission-blocking anti-
malarial clinically available worldwide, seems to equally target
the parasite’s redox system; this drug displays marked activity
against gametocytes of all species of human malaria, includ-
ing multi-resistant P. falciparum strains, and is also effective
against all exoerythrocytic forms of the parasite, including hyp-
nozoites, dormant liver forms responsible for relapse of vivax
and ovale malaria. Unfortunately, as many other clinically rel-
evant antimalarials, primaquine is often associated with seri-
ous adverse effects, in consequence of its toxic metabolites
(Vale et al., 2009).
Another drawback in antimalarial containment has emerged
from misuse of available drugs, and marketing of fake ones,
leading to widespread resistance. This has been the major fac-
tor behind chloroquine’s loss of prominence in the antimalar-
ial arsenal from the 1980s onward, and is also becoming a
cause of concern regarding 21st century ﬁrst-line artemisinin-
based combination therapies (ACT): the ﬁrst signs of plasmodial
resistance to artemisinin emerged in Southeast Asia in 2008
(Dondorp et al., 2009).
The above explains why malaria eradication is still out of reach
and why the need to feed the antimalarial drug pipeline remains
an urgent problem. In this connection, membrane-active peptides
(MAP), such as most AMP, may offer interesting solutions, as by
having cell membranes as their primary targets, their action will
be harder to ﬁght back by malaria parasites.
ANTIMICROBIAL PEPTIDES WITH ANTIMALARIAL PROPERTIES
There have been numerous reports on peptides active against var-
ious cultured stages of malaria parasites and/or in animal models
of malaria. The range of size, AA composition, and secondary
structure of such peptides is impressive, going from dipeptides up
to polypeptides large enough to be considered as proteins. Anti-
malarial activity has been described for several substrate analogs
of different plasmodial peptidases involved in host hemoglobin
degradation, host-cell invasion and egress, and intracellular
housekeeping (Blackman, 2004; Wegscheid-Gerlach et al., 2010).
One interesting example is that of the ankyrin peptide (AnkP), a
potent inhibitor of the major cysteine protease of P. falciparum,
falcipain-2, which was delivered into parasite-infected red blood
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FIGURE 1 | Life cycle of malaria parasite. Malaria transmission occurs through a vector, the female Anopheles mosquito, which ingests gametocytes (the
only infective form to mosquitoes) when feeding on infected blood (adapted with permission from Klein, 2013).
cells (PfRBC) via the Antennapedia homeoprotein internalization
domain; this served to demonstrate not only the antimalarial
properties of peptidase substrate analogs like AnkP, but also the
potentially useful role of another class of MAP, the cell-penetrating
peptides/proteins (CPP), for intracellular delivery of antimalar-
ials (Dhawan et al., 2003). There have been also many reports
on synthetic peptides or protein fragments with speciﬁc targets
at parasite/host or parasite/vector interfaces, for instance, pep-
tide fragments of adhesins that are involved in host-cell invasion
(Malpede and Tolia, 2014).
Many broad-spectrum AMP from various sources, including
anopheline mosquitoes (malaria vectors), have also been found
to exhibit different degrees of antimalarial action (Bell, 2011).
The fact that Plasmodia are eukaryotes may appear incompat-
ible with the general notion that selective AMP preferentially
target negatively-charged prokaryote membranes; however, the
phospholipid composition of membranes from intraerythro-
cytic parasites are markedly different from those of their host
eukaryote cells, RBC; moreover, upon infection by P. falciparum,
RBC undergo signiﬁcant changes in their membranes, whose
composition gets closer to that of parasitic membranes (Hsiao
et al., 1991). For instance, as compared to healthy RBC, PfRBC
have increased contents of phosphatidylinositol and phosphatidic
acid, and decreased contents of sphingomyelin, whereas phos-
phatidylethanolamines remain more or less unchanged (Hsiao
et al., 1991). In other words, PfRBC membranes differ from those
of healthy RBC; this, together with the fact that mechanisms of
antimalarial action by AMP remain unknown, explains why the
paradox of AMP exhibiting antiprotozoal action is only apparent.
This comes in agreement with ﬁndings from Gelhaus et al. (2008),
who found that NK-2, a small cationic AMP,while hardly affecting
healthy RBC, promptly internalized PfRBC, affecting the viabil-
ity of intracellular parasites; studies with liposomes, by the same
authors, revealed a phosphatidylserine-dependent lysis by NK-2,
which indicates that small cationicAMPmaybe selective toPfRBC,
hence, emerging as a potential new class of antimalarials. In fact, a
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range of natural and synthetic AMP were found to have promising
anti-plasmodial properties (Table 1), showing that modulation of
the innate immune response is an effective approach to novel pep-
tide anti-infective agents (Haney and Hancock, 2013). Another
relevant example is that of phylloseptin-1(PS-1), an AMP capable
to control the growth and cause in vitro destruction of P. falci-
parum, at the concentration of 16 μg/mL, well-below the levels at
which this peptide is toxic to mammalian cells (Kückelhaus et al.,
2009). More examples of antimalarial AMP are next revised in
higher detail.
Cecropins and derivatives
Cecropins, from the moth Hyalophora cecropia, disturb the devel-
opment of oocysts into sporozoites, with a 50% lethal dose
between 0.5 and 1 μg/μL (Gwadz et al., 1989). Synthetic deriva-
tives of cecropins have also been produced and analyzed for
their effects against malaria: SB-37, highly similar to cecropin
B, and Shiva-1, with 40% homology to the same cecropin from
H. cecropia, were signiﬁcantly lytic to P. falciparum blood stage
forms at 50 μM; still, while SB-37 was equipotent to cecropin
B, Shiva-1 was twice as active as this cecropin (Jaynes et al.,
Table 1 | Antimicrobial peptides reported as active against Plasmodium spp. parasites.
Peptide Sequence/origin/reference Activity
CA(1-13)M(1-13) KWKLFKKIEKVGQGIGAVLKVLTTGL Cecropin A/melittin hybrid (Frederik
et al., 1989)
IC50 10 mM (PfRBC)
Cecropin B KWKVFKKIEKMGRNIRNGIVKAGPAIAVLGEAKALG Hyalophora cecropia
(Gwadz et al., 1989)
81–94% abortion of oocyst development
(Plasmodium spp.) at 0.5 μg/μL (128 μM)
Defensin A ATCDLLSGFGVGDSACAAHCIARGNRGGYCNSKKVCVCRN Aedes aegypti
(Kokoza et al., 2010)
∼85% inhibition of oocyst proliferation in
transgenic mosquitoes (P. gallinaceum)
Dermaseptin DS3 X-ALWKNMLKGIGKLAGKAALGAVKKLVGAES Phyllomedusa sauvagii
(dermaseptin derivative) (Ghosh et al., 1997)
IC50 0.8–1.5 μM (PfRBC)
Dermaseptin DS4 X-ALWMTLLKKVLKAAAKAALNAVLVGANA Phyllomedusa sauvagii
(dermaseptin derivative) (Ghosh et al., 1997)
IC50 0.27–2.2 μM (PfRBC)
D -HALO-rev AKKLOHALHOALLALOHLAHOLLAKK Synthetic (Mason et al., 2009) IC50 0.1 μM (PfRBC)
Drosomycin DCLSGRYKGPCAVWDNETCRRVCKEEGRSSGHCSPSLKC-WCEGC
Drosophila melanogaster (Tian et al., 2008)
70% gametocytes inhibition at 20 μM (P.
berghei )
Gambicin MVFAYAPTXARXKSIGARYXGYGYLNRKGVSXDGQTTIN-
SXEDXKRKFGRXSDGFIT Anopheles gambiae (Vizioli et al.,
2001)
54.6% ookinetes killed at 10 μM (P. berghei )
IDR-1018 VRLIVAVRIWRR Bactenicin derivative (bovine neutrophils) (Wieczorek
et al., 2010)
Protection against cerebral malaria
Dermaseptin K4K20-S4 ALWKTLLKKVLKAAAKAALKAVLVGANA Phyllomedusa sauvagii
(dermasepin S4 derivative) (Krugliak et al., 2000)
IC50 0.2 μM (PfRBC)
Dermaseptin K4-S4(1-13)a ALWMTLLKKVLKA Phyllomedusa sauvagii (Dermasepin S4 derivative)
(Krugliak et al., 2000)
IC50 6 mM (PfRBC)
Dermaseptin NC7-P H2N-(CH2)6-CO-ALWKTLLKKVLKA-NH2 Phyllomedusa sauvagii
(dermaseptin K4-S4(1-13)a derivative) (Efron et al., 2002)
IC50 5.3 μM (PfRBC, ring stage); 6.2 μM
(PfRBC, trophozoites)
Magainin 2 GIGKFLHSAKKFGKAFVGEIMNS Xenopus laevis (Frederik et al., 1989) 82–95% abortion ofoocyst development
(Plasmodium spp.) at 0.5 μg/mL (203 μM)
NK-2 KILRGVCKKIMRTFLRRISKDILTGKK Synthetic (Gelhaus et al., 2008) IC50 1–10 μM (PfRBC)
SB-37 MPKWKVFKKIEKVGRNIRNGIVKAGPAIAVLGEAKALG Synthetic cecropin B
derivative (Jaynes et al., 1988)
IC50 ∼50 μM (PfRBC)
Scorpine GWINEEKIQKKIDERMGNTVLGGMAKAIVHKMAKNEFQ-
CMANMDMLGNCEKHCQTSGEKGYCHGTKCKCGTPLSY Pandinus
imperator (Conde et al., 2000; Carballar-Lejarazu et al., 2008)
IC50: 1 μM (P. berghei ookinetes); ∼10 μM (P.
berghei gametes)
Shiva-1 MPRWRLFRRIDRVGKQIKQGILRAGPAIALVGDARAVG Synthetic cecropin
B derivative (Jaynes et al., 1988)
IC50 ∼20 μM (PfRBC)
Vida1 Vida 2 Vida 3 KWKKFKKGIGKLFV KWPKFKKGIPWLFV KWPKFRRGIPFLFV Synthetic
cecropin B/melittin hybrids (Arrighi et al., 2002)
≥60% mortality of young P. berghei ookinetes
at 50 μM
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1988). The effect of another cecropin-like peptide, Shiva-3,
on in vitro ookinete development and on the early sporogo-
nic stages of P. berghei in the midgut of Anopheles albimanus
mosquitoes was investigated; peptide concentrations of 75 and
100 μM were effective in reducing ookinete production and
the number of infected mosquitoes in almost all experiments
(Rodriguez et al., 1995).
Hybrids of non-hemolytic cecropinswith the potent bee venom
toxin melittin have been found to inhibit RBC re-invasion by
P. falciparum; an example of one such hybrid is that of CA(1-
13)M(1-13), which is an order of magnitude more potent than
magainin, cecropin A, and cecropin B, and is active in the
5–10 μM range (Frederik et al., 1989). More recent cecropin-
melittin hybrids Vida1 (mainly consisting of α-helices), Vida2
(essentially composed by β-sheets), and Vida3 (a combina-
tion of coils and sheets) were developed and tested against P.
berghei and P. yoelii gametocytes. The mortality rate of: Vida1
was 65% on young ookinetes (10 h), Vida2 was 60–70% on
maturing ookinetes (14 and 24 h), and Vida3 was higher than
60% throughout the entire developmental period (Arrighi et al.,
2002). The antimalarial activity of Vida3 was associated to block-
age of Plasmodium oocyst development, and the peptide was
further found as toxic to Anopheles gambiae cells at 25 μM
(Carter et al., 2013).
The exact molecular mechanisms of membrane activ-
ity of cecropins have been under debate for more than
30 years, with two general models being proposed: forma-
tion of transmembrane pores, and the carpet model (Melo
et al., 2009). A recent study demonstrates that cecropins A
and B produce well-deﬁned ion channels of different con-
ductance levels in bilayer lipid membranes; further increase
in peptide concentration causes destabilization and subse-
quent breakdown of the bilayer, showing that formation of
pores is a ﬁrst stage of membrane destabilization by these
two cecropins, while accumulation of a dense peptide car-
pet precedes complete bilayer disintegration (Eﬁmova et al.,
2014).
Amphibian antimalarial peptides: dermaseptins, magainins
Dermaseptins, from the skin of Phyllomedusa frogs, are highly
active against intraerythrocytic forms of different P. falciparum
strains, with IC50 values between 0.8 and 2.2 μM (Matsuda
and Koyasu, 2000). A truncated dermaseptin derivative was
found to exert anti-P. falciparum activity within less than 1 min
after exposure, involving permeabilization of the host cell mem-
brane (Bell et al., 2006). In order to decrease hemolytic activity
of dermaseptins, aminoheptanoyl derivatives were synthesized;
a screening against P. falciparum revealed higher activity for
the more hydrophobic dermaseptin derivatives, some of which
showing signiﬁcant selectivity between antiplasmodial activ-
ity versus hemolytic activity (Efron et al., 2002; Gavigan et al.,
2003).
Following discovery of antiplasmodial activity of the 28-
residue AMP dermaseptin S4 (Ghosh et al., 1997), a derived
13-residue AMP, K4-S4(1-13), was found to display consider-
able in vitro efﬁcacy on P. falciparum (Krugliak et al., 2000).
The antiplasmodial action of K4-S4(1-13) was fast and shown
to be mediated by permeabilization of host cell plasma mem-
brane. Although K4-S4(1-13) was less hemolytic to healthy
RBC than to PfRBC, selectivity was not high enough and
turned evident the necessity to develop additional deriva-
tives active on parasites but with minimal threat to normal
erythrocytes. Recently, acyl derivatives of K4-S4(1-13) were
shown to have increased antiplasmodial activity, but the most
potent of them was still signiﬁcantly hemolytic (Dagan et al.,
2002).
Antimalarial peptides from insect vectors of parasitic diseases
Antimicrobial peptides of insect origin have been found which
display antimalarial properties. Drosomycins, isolated from
Drosophila melanogaster, are an example of insect antimalar-
ial peptides. Drosomycins were tested against development
of P. berghei ANKA gametocytes, with drosomycin-2 show-
ing 30% inhibition at 20 μM, whereas prototype-peptide dro-
somycin showed over 70% inhibition at that same concentration
(Tian et al., 2008).
The most interesting source of antimalarial AMP concerns
insects that are themselves the vectors of parasitic diseases,
like anopheline mosquitoes, responsible for malaria transmis-
sion. It seems logical that such insects need to be equipped
with a considerable defense system against the parasites they
carry. In Anopheles mosquitoes, there are different known pro-
tection mechanisms, such as (i) upregulation of NO synthase,
(ii) melanotic encapsulation in refractory mosquitoes that inhibit
parasite development (Collins et al., 1986; Vijay et al., 2011),
and production of AMP that might play an important role
in refractoriness. In the major vector of P. falciparum in sub-
Saharan Africa, A. gambiae, defensin, cecropin, and gambicin
AMP have been found (Vizioli et al., 2000; Blandin et al., 2002;
Kim et al., 2004).
The A. gambiae cecropin gene is mainly expressed in the
mosquito midgut in hemocyte-like cells, and its levels are sig-
niﬁcantly raised within 2 h of infection (Vizioli et al., 2000).
The activity of the A. gambiae cecropin against Plasmod-
ium was studied by creating transgenic mosquitoes with cecA
expression under the control of the Aedes aegypti carboxypep-
tidase promotor. The number of oocysts was reduced by
60% compared to the non-transgenic mosquitoes (Kim et al.,
2004).
Gambicin, extracted from two A. gambiae cell lines, is an
immune-induced peptide predominantly expressed in the ante-
rior midgut compartment, thorax, and abdomen. The mature
gambicin peptide is active against Gram-positive and Gram-
negative bacteria, ﬁlamentous fungi, and P. berghei ookinetes
(Vizioli et al., 2001).
Other mosquito vectors, such as A. aegypti, responsible for
transmission of dengue and yellow fever viruses, produce AMP
with antimalarial activity. A. aegypti releases three 40-AA long
defensins (Def A to C) and cecropin A in response to bacterial
infections (Lowenberger et al., 1995,1999). In transgenicA. aegypti
mosquitoes with co-overexpression of A. aegypti cecropin A and
defensin A, P. gallinaceum oocyst proliferation was signiﬁcantly
inhibited as compared to wildtype mosquitoes (Lowenberger,
2001; Kokoza et al., 2010).
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The strategy to produce transgenic mosquitoes that het-
erologously express AMP in order to interrupt Plasmodium
transmission was also tested for scorpine, an AMP from the
venom of Pandinus imperator scorpions. Scorpine belongs to
a group of ion channel blockers with high activity against P.
berghei ANKA gametes and ookinetes (ED50 of 10 and 0.7 μM,
respectively; Conde et al., 2000) that was shown to disrupt the
sporogonic development of P. berghei. The scorpine gene was
introduced into a vector for generation of transgenic ﬂies resis-
tant to infection by Plasmodia. The ﬁnal aim of this work
was to incorporate this gene under the promoter of prote-
olytic enzymes of the mosquito digestive tract, for synthesis
and release of toxic peptide(s) into the stomach of freshly fed
mosquitoes potentially carrying Plasmodium gametes; the pres-
ence of recombinant scorpine could be conﬁrmed in transgenic
A. gambiae cell supernatants (Possani et al., 2002). At low concen-
trations, recombinant scorpine reduced the number of ookinetes
formed after mosquito feeding on P. berghei-infected mouse
blood. Scorpine had highest effects (98% inhibition) when added
during gamete formation and fertilization (Carballar-Lejarazu
et al., 2008). In view of this, strategies to deliver AMP into
the mosquitoes to interrupt the sporogonic cycle are relevant;
one such strategy has been reported that uses symbiotic bacte-
ria that live in the mosquito’s midgut: the transgenetic symbiont
Pantoea agglomerans, expressing recombinant AMP Shiva-1 and
scorpine, completely inhibited P. falciparum sporogonic cycle
(Wang et al., 2012).
Circular AMP with antimalarial properties
There is a signiﬁcant number of cyclic AMP and derived macro-
cycles that have shown antimalarial properties. The potentially
large, but structurally often well-deﬁned conformational space
sampled, combined with the variety of AA, renders cyclic
peptides ideally suited to interact with many receptors or to
interfere with protein/protein interactions (Katoh et al., 2011;
Giordanetto and Kihlberg, 2014). In this context, cyclosporin
A (CsA, 1 in Figure 2) is a well-characterized immunosup-
pressant hydrophobic peptide (Borel et al., 1996) that was ear-
lier found to have antimalarial activity against P. berghei and
P. yoelii rodent malaria and on cultured P. berghei, P. falci-
parum, and P. vivax parasites (Nickell et al., 1982). More recently,
nine CsA-resistant P. falciparum clones were isolated, of which
three had lesions in cyclophilin genes and two in calcineurin-
subunit genes (Kumar et al., 2005). The two cyclophilins affected
had been identiﬁed as cyclosporin-binding proteins in P. fal-
ciparum (Gavigan et al., 2003), but CsA may also have other
targets in Plasmodia, since, it has a number of different
known targets including the mammalian P-glycoprotein trans-
porter. In agreement with this hypothesis, sequence polymor-
phisms in (and possibly expression levels of) a P. falciparum
P-glycoprotein homolog were found to affect susceptibility to CsA
(Gavigan et al., 2007).
Thiostrepton (2 in Figure 2), a cyclic thiopeptide, has reported
IC50 ranging from 1.8 to 17 μM against parasite growth and pro-
tein synthesis of P. falciparum, though this is suggested to be an
overestimate since solubility of the compound in culture medium
is poor (Clough et al., 1997; McConkey et al., 1997). IC50 values for
thiostrepton derivatives were 0.77 μM and above against P. falci-
parum (Schoof et al., 2010), and other thiopeptides were described
as displaying nanomolar IC50 against organellar protein synthesis
in the same strain: micrococcin (3 nM), GE2270A (300 nM), and
amythiamicin A (10 nM; Clough et al., 1999).
Most recently, three new macro-heterocyclic AMP, balgacy-
clamides A–C, were isolated from Microcystis aeruginosa EAWAG
251 and thoroughly characterized. Balgacyclamides A (3 in
Figure 2) and B (4 in Figure 2) were evaluated for their antipar-
asitic activity and found to display micromolar IC50 activity
against the chloroquine-resistant strain K1 of P. falciparum (9.0
and 8.2 μM, respectively) with good selectivity compared to their
cytotoxicity (Portmann et al., 2014).
Another recent report on a cyclic antimalarial peptide con-
cerns the Gly-rich cyclic octapeptide pohlianin C (5 in Figure 2),
whose synthesis provided conﬁrmation of the structure of this
natural product. Evaluation against P. falciparum showed moder-
ate antiplasmodial activity, consistent with data obtained from the
natural sample. In addition, the synthesis of three analogs revealed
that the antiplasmodial activity of pohlianin C can be preserved
or increased with simpliﬁed structures (Lawer et al., 2014).
Other synthetic antimalarial AMP: from NK-2 to IDR-1018
NK-2 was one of the ﬁrst synthetic AMP found to have anti-
parasitic properties. NK-2 is a shortened version of the mam-
malian protein NK-lysin, comprising its residues 39–65, and long
known to display lytic activity against the fungal pathogen Can-
dida albicans and a variety of Gram-positive and Gram-negative
bacteria, while exhibits virtually no hemolytic or cytotoxic activity
against human cells (Andrä and Leippe, 1999). In a study aimed
at determining the antimicrobial spectrum of both NK-lysin and
NK-2, activity against the protozoan parasite Trypanosoma cruzi
was observed (Jacobs et al., 2003). Later, NK-2 was found to be
hemolytic toPfRBCabove∼1μM,while harmless for healthyRBC
up to 10μM,alongwith evidence that parasitemembrane also suf-
fered permeabilization at 5 and 10 μM. The selective lytic activity
of NK-2 on PfRBC was further demonstrated by observation that
ﬂuorescently labeled NK-2 binds to infected erythrocytes and to
parasites, but not to healthy erythrocytes (Gelhaus et al., 2008).
Another synthetic AMP with antimalarial activity is D-HALO-
rev. This design peptide possesses 26 AA with an even distri-
bution of hydrophobic and charged residues, including non-
proteinogenic ornithine (O, Orn), a Lys homolog. D-HALO-rev
shows an IC50 value of 0.1 μM against erythrocytic stages of P.
falciparum, being able to penetrate PfRBC at sublytic concen-
trations and kill intraerythrocytic parasites (Mason et al., 2009).
Similar results were obtained for an analog resulting from incor-
poration of Pro, Phe, and D-AA residues (D-Halo-P8F-rev),
which showed reduced toxicity toward healthyRBCandﬁbroblasts
(Mason et al., 2009).
A further step forward in this ﬁeld was recent disclosure of
the ability of synthetic peptide IDR-1018 to provide protection
against cerebral malaria (Achtman et al., 2012). IDR-1018 is a
12-residue innate defense regulator analog of bactenecin, a cathe-
licidine from bovine neutrophils. It putatively owes its action to
translocation across cell membrane and impairment of an intra-
cellular target (Wieczorek et al., 2010). IDR-1018 was selected for
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FIGURE 2 | Circular peptides with antimalarial activity. Full molecular
structure is shown. Amino acid labeling, with the corresponding three-letter
code, has been added where applicable:Abu, 2-aminobutyric acid;Ala,
L-alanine; D-Ala, D-alanine; Dha, dehydroalanine; Gly, glycine; Ile,
L-isoleucine; Phe, L-phenylalanine;Thr, L-threonine;Val, L-valine; MeGly,
N-methylglycine [also known as sarcosine (Sar)]; MeLeu, N-methylleucine;
MeVal, N-methylvaline. Uncommon amino acid residues or their analogs not
possessing any internationally approved abbreviation were kept unlabeled.
screening in cerebral malaria given its anti-inﬂammatory capa-
bilities and low toxicity, and found to protect 56% of infected
mice from cerebral malaria after prophylactic intravenous admin-
istration. When combined with the antimalarial pyrimethamine-
chloroquinemedicine, IDR-1018boostedprotection fromcerebral
malaria in 41–68% of infected mice (Achtman et al., 2012).
PROMISES AND PITFALLS OF PEPTIDE ANTIMALARIALS: FROM
CONVENTIONAL PHARMACEUTICAL TO BIOTECHNOLOGICAL
APPROACHES
Examples of peptide drug candidates entering clinical trials remain
scarce, as compared to those of small molecular drug candidates;
despite a few suchpeptides display antimalarial activity (pexiganan
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in phase III, omiganan and OP-145 in phase 2, and NVB302 in
phase I), their involvement in clinical trials is directed to disorders
other thanmalaria (Fox, 2013). This ismainly due to the tradition-
ally cautious attitude of pharma companies toward peptide-based
drugs, given that:
• peptides seldom are orally bioavailable given their usually high
molecular weight, extensive enzymatic degradation (proteoly-
sis) and binding to plasma proteins;
• peptide production costs are high and synthesis scale-up is not
easy, which will result in medicines too expensive, especially if
targeted at low-income countries.
Therefore, until recent years, pharma companies have mostly
put their bets on small drug candidates, with molecular weights
tipically below 500 Da and oral bioavailability, leaving much larger
biomolecule-based candidates put aside, as molecules with over
5000Da arenot orally bioavailable, amongother limitations. How-
ever, small drugs often suffer from reduced selectivity, leading to
unwanted off-target side effects; in turn, peptides and proteins
are usually characterized by an extraordinary speciﬁcity for their
targets, which may largely compensate for their low bioavailabil-
ity, poor permeability and susceptibility to metabolic inactivation
(Craik et al., 2013).
In the particular case of malaria, from World War II to the
present, a huge plethora of small molecules nicely obeying the
Lipinski’s rule of 5 for orally bioavailable drugs (Lipinski et al.,
1997) has been continuously feeding the antimalarial drugpipeline
(Teixeira et al., 2014). Nonetheless, control of the disease remains
out of reach, especially due to toxicity and resistance issues (Wells
and Poll, 2010). Moreover, Lipinski’s rule applies only to drug
absorption by passive diffusion through cell membranes, i.e., it
is not predictive for compounds actively transported by trans-
membranar proteins (Leeson, 2012). Altogether, this emphasizes
the need for highly speciﬁc antimalarials, preferably with no
or reduced propensity to elicit parasite resistance, and also that
unconventional drugs, like peptides, may eventually ﬁll such need,
provided suitable strategies to overcome some challenges posed
by peptide drugs are found. Fortunately, the 21st century emerged
along with the ﬁrst evidences of a paradigm shift in this ﬁeld:
between 2011 and 2012, nineteen peptide drugs were approved in
the US, and the remarkable expansion of peptide therapeutics
development in the late 1990s and 2000s led to an unprece-
dented number of marketing approvals in 2012, while providing
a robust pipeline that should deliver numerous approvals during
the remainder of the 2010s; in the US, annual sales of peptide
drugs exceed 13 bilion dollars, representing 1.5% of global drug
sales. In Europe, Germany and the UK account for 63% of the
peptide therapeutics market, with France, Italy, Scandinavia, and
Spain making up the rest of the major European salers in this area
(Kaspar and Reichert, 2013).
In addition to the above, peptide and protein biotechnol-
ogy continues evolving at full speed, with the most prominent
example today being that of therapeutic antibodies (Leavy, 2010).
Other biotechnological approaches include, e.g., bioactive pep-
tide grafting onto suitable biocompatible carriers to enhance
peptide bioavailability at the site of action (Costa et al., 2011;
Lax and Meenan, 2012a,b; Maia et al., 2014), or development
of long−acting release forms of peptides such as somatostatin
analogs through encapsulation in biodegradable polymers requir-
ing injection only at extended intervals to raise patient’s com-
pliance (Anthony and Freda, 2009). Genetic engineering and
recombinant biotechnology are changing pharma’s perspective
toward peptide therapeutics, as genetically engineered proteins
offered a window to previously untreatable medical conditions
that convinced this industry to conform with the need to develop
drugs that could not be administered through the oral route;
it also motivated an intense search for alternative (to injection)
drug delivery platforms to meet patient’s acceptability, and offers
an useful alternative to chemical production of large (>40 AA)
peptides, whose synthesis is challenging and expensive, even
at low scale; hence, recombinant biotechnology will play an
increasingly important role in peptide manufacturing mainly
due to quantity requirements (Lax, 2010). Still, biotechnology
will complement, and not replace, chemical peptide synthesis
in the production of peptide therapeutics: cost of large-scale
peptide chemical synthesis, in particular through the most pop-
ular solid−phase procedures based on Fmoc−chemistry, has
signiﬁcantly decreased over the past 15 years, mainly due to
technological evolution of automated synthesizers and chromato-
graphic systems; moreover, many highly speciﬁc and potent
peptide therapeutics require daily doses of only a few micro-
grams; furthermore, when applicable, chemical peptide synthesis
is more easily scalable for manufacturing at up to a multi−10
kg or 100−kg scale, and is less demanding in terms of process
development, and less personnel intensive in terms of pro-
duction, quality assurance and regulatory affairs; last, but not
least, chemical approaches are far superior to biotechnologi-
cal ones regarding ﬂexibility in the design of analogs requir-
ing unnatural amino acids or non−proteogenic building blocks
(Lax, 2010).
In summary, peptide therapeutics are reaching a maturity
level that emphasizes their potential interest against a wide diver-
sity of medical challenges. While, about half of the peptides in
clinical trials target indications in oncology, metabolic, cardiovas-
cular and infectious diseases, the total range of therapeutic areas
addressed encompasses a wide assortment of medical disorders
from endocrinological lesions through to pain and hematology
(Kaspar and Reichert, 2013). In the particular case of malaria,
development of peptide therapeutics is still at its earliest infancy,
but several cutting-edge approaches to antimalarial peptides are
emerging today. One recent example followed demonstration that
PfSERA5 plays an important role in parasite development; in
this study, a number of peptides from the N- and C-terminal
regions of PfSERA5 active domain was synthesized and evaluated
as antiplasmodials. These peptides reduced activity of the recom-
binant enzyme and co-localized with PfSERA5 within the parasite,
thereby indicating the speciﬁc inhibition of PfSERA5 activity. Such
results reinforce the role of PfSERA5 for the intraerythrocytic
development of malaria parasites and unveil the relevance of this
enzyme as target for new peptide antimalarials (Kanodia et al.,
2014). In view of this, and considering the recent unveiling of the
P. falciparum genome (Boddey et al., 2013), we can only expect the
future to conﬁrm that a new class of antimalarial drugs, based on
AMP, will rise.
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CONCLUDING REMARKS
This review highlights that peptides are being put forward as
one potential novel class of antimalarial drugs. A range of AMP
exhibit antimalarial activity on malarial parasites in their blood
or mosquito stages or both. Some peptides naturally occurring in
mosquitoes affect the parasites transmitted by those insect vectors,
but it has been difﬁcult to determine the magnitude of their effects
in the natural setting. However, this ﬁeld of research is a recent one,
and more systematic studies are needed to identify the structural
variants that are most potent and selective on cultured parasites
and to test them in vivo. Better understanding of mechanisms of
action would help to guide the design of new peptides and the
development of in vitro assays with which to compare their target-
binding afﬁnities. Some antimalarial peptides are believed to act
selectively on infected erythrocyte and/or intraerythrocytic para-
site membranes, in which case the appropriate model membrane
systems are required. This means that another well-known family
of MAP, besides AMP,may soon gain also relevance in antimalarial
approaches: that of CPP. These can translocate into cells with-
out causing membrane damage, therefore being useful carriers
for therapeutic cargoes to treat various conditions (De Figueiredo
et al., 2014). Membrane-active AMP and CPP show signiﬁcant
similarities in charge, structure, and initial steps of interactions
with membranes; moreover, CPP are being identiﬁed with anti-
malarial activity per se, e.g., TP10 that has broad-spectrum activity
against both blood and mosquito stages of P. falciparum (Arrighi
et al., 2008). In conclusion,MAP seem to be paving the way toward
establishment of useful peptide-based drugs against parasitic
infections.
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